

**From:** [Jarvis, Candace](#)  
**To:** [James L'Italien, PhD \(jlitalien@avexis.com\)](#)  
**Cc:** [Nancy Boman](#); [Wang, Wei \(FDA\)](#); [Byrnes, Andrew](#); [Jarvis, Candace](#)  
**Subject:** BLA 125694/0| AveXis, Inc| Information Request 45 ( Please Respond by April 10, 2019)  
**Date:** Wednesday, March 27, 2019 1:21:51 PM  
**Attachments:** [image013.png](#) **Importance:** High

---

Good afternoon Dr. L'Italien,

We received and reviewed your responses (Amendment, STN 125694/0.52, CBER received on 26Mar2019) to address questions in the CBER Information Request (IR, dated 14Mar2019). Your following responses were incomplete. Please provide the requested information by 10Apr2019:

1. Your response to the Question #1 in the CBER IR (dated 14Mar2019) is incomplete. You did not provide the requested information. Please note equipment surfaces that contact sterilized drug product or its sterilized containers or closures must be sterile so as not to alter purity of the drug product (211.113). In addition, where reasonable contamination potential exists, surfaces that are near the sterile product should also be rendered free of viable organisms. Please update your BLA submission Section 3.2.A.1 to include a description of your procedural controls for the qualification and routine control of (b) (4), as a contract sterilizer for your aseptic filling equipment.
2. Your response to the Question #3 in the CBER IR (dated 14Mar2019) is incomplete. You did not provide the requested information. Please address the suitability of your Container Closure Integrity Test method (i.e. CCIT by (b) (4)) to detect the potential compromised container closure integrity due to loss of elastic properties of the CL Butyl stopper (material number (b) (4)) during the long term (up to (b) (4)) storage at  $\leq -60^{\circ}\text{C}$ . **Information provided should address the potential regaining of elastomeric properties of the stopper and the re-sealing of the container closure system once thawed during long term storage.**

Please kindly acknowledge receipt.

*Regards,*

*Candace N. Jarvis*  
*Regulatory Project Manager*  
*Center for Biologics Evaluation and Research*  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**

Tel: 240-402-8315

[candace.jarvis@fda.hhs.gov](mailto:candace.jarvis@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.